HESTERBIO finished at ₹2,545, up 20.16% from ₹2,118, and the session stood out for much heavier activity than usual: turnover was about ₹120.3 crore versus a 20-day average near ₹5.7 crore, with volume at 4.82 lakh shares. The stock was the top gainer in the supplied tape for 2026-07-13 and sat in the Healthcare sector, Pharmaceuticals & Biotechnology industry. No direct company-specific headline or fresh event was provided alongside the price move, so the day’s advance cannot be tied to a confirmed catalyst from the supplied context. The move also needs to be read as a same-day market snapshot, not a broader trend signal, because no additional history or intraday detail was provided. Source: HESTERBIO price and turnover data.
Aurific Market Desk
Post-closeHESTERBIO jumps 20.2% on heavy turnover; no catalyst supplied
HESTERBIO led the gainers with a 20.16% rise to 2,545, while turnover surged to about ₹120.3 crore versus a 20-day average near ₹5.7 crore. No company-specific news was supplied with the move.
By the Aurific Market DeskJuly 13, 20261 min readAI-assisted
Members only
Continue reading with Aurific
This Aurific Market Desk note — the full analysis, live exhibits and desk read — is available to signed-in Aurific members. Sign in to keep reading, or request access.
Continue reading
More essays
The Slump Sale Arbitrage: Corporate Action Outperforms Macro Anxiety
As a hawkish Fed pause and global chip rout dent sentiment, domestic corporate actions and earnings are driving sharp, idiosyncratic outperformance.
July 30, 2026
Indian IT Defies the Global AI Hangover as M&A Heat Returns
Local tech and capital goods stocks surged on earnings and deal-making, decoupling from the broader Asian sell-off triggered by global AI volatility.
July 29, 2026